source
- SK Biopharma signs $795 million licensing deal with Biohaven for epilepsy therapy opakalimSK Biopharma has entered a licensing agreement with Biohaven Pharmaceuticals to acquire worldwide rights to the Kv7 ion channel activator opakalim (BHV-7000) for epilepsy. The deal provides an upf…
- MassBio CEO warns 2025 may be biotech's toughest year amid China and NIH challengesMassachusetts is widely regarded as the epicenter of biotech because of its world‑class research institutions and vibrant startup ecosystem. MassBio CEO Kendalle Burlin O’Connell said 2025 will pr…